RxDoctor Payments Data

Emile Sabbagh, MD

Internal Medicine · Westlake, OHNPI 1831165521

Payments from drug & device makers

$265in general payments, 2019–2025

Across 10 payments — averaging $26.45 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Radius Health, Inc.$124
  • Avanir Pharmaceuticals, Inc.$32
  • Nestle Healthcare Nutrition Inc.$24
  • Sunovion Pharmaceuticals Inc.$22
  • Lilly USA, LLC$17
  • Johnson & Johnson$17
  • plus $28 from 2 others

What the payments were for

  • Food & beverage$265100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$265 in reported general payments places this provider in the 55th percentile of 4,428 internal medicine providers in Ohio.

See all internal medicine providers in Ohio

Medicare billing

Part B allowed, 2024
$257,138
Medicare patients
558
Services billed
2,484

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban584$211,789
Invega SustennaPaliperidone Palmitate24$81,870
JanuviaSitagliptin Phosphate113$48,771
Trelegy ElliptaFluticasone/Umeclidin/Vilanter67$46,534
XareltoRivaroxaban82$31,381
Divalproex Sodium537$29,866
JardianceEmpagliflozin69$26,701
TrulicityDulaglutide27$24,653
TradjentaLinagliptin54$21,827
MounjaroTirzepatide26$21,254
Memantine Hcl467$18,291
FarxigaDapagliflozin Propanediol42$17,163
Mirtazapine719$16,905
MyrbetriqMirabegron43$16,135
Atorvastatin Calcium1,097$14,802

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Johnson & JohnsonInvega Sustenna, Xarelto, Procrit$17$119,529117 claims
Lilly USA, LLCTrulicity, Mounjaro$17$45,90853 claims
AstraZenecaFarxiga$16$17,16342 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 55th percentile of 4,428 internal medicine providers in Ohio.

Other internal medicine in Westlake

See the full list for Ohio

Where these figures come from

Is this you, or does something look wrong? →